Tour­ma­line Bio's heart drug cuts in­flam­ma­tion as it seeks to com­pete with No­vo, CSL's as­sets 

Tour­ma­line Bio’s ex­per­i­men­tal drug for ath­er­o­scle­rot­ic heart dis­ease re­duced mark­ers of in­flam­ma­tion in the blood in a mid-stage study.

The com­pa­ny must now show the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER